Jump to content

Nagoya Protocol

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by 41.186.78.178 (talk) at 09:01, 26 November 2022 (→Obligations). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Nagoya Protocol
Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from their Utilization to the Convention on Biological Diversity
  Parties
  signed, but not ratified
  non signatory, but Biological Diversity Convention party
  non signatory, non-Biological Diversity Convention party
Besides several member states, the EU is also a party (not on map)
TypeEnvironmental
Signed29 October 2010
LocationNagoya, Japan
Effective12 October 2014
Condition50 ratifications
Signatories92
Parties137
DepositarySecretary-General of the United Nations
LanguagesArabic, Chinese, English, French, Russian and Spanish

The Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from their Utilization to the Convention on Biological Diversity, also known as the Nagoya Protocol on Access and Benefit Sharing (ABS) is a 2010 supplementary agreement to the 1992 Convention on Biological Diversity (CBD). Its aim is the implementation of one of the three objectives of the CBD: the fair and equitable sharing of benefits arising out of the utilization of genetic resources, thereby contributing to the conservation and sustainable use of biodiversity. It sets out obligations for its contracting parties to take measures in relation to access to genetic resources, benefit-sharing and compliance.

The protocol was adopted on 29 October 2010 in Nagoya, Japan and entered into force on 12 October 2014. As of April 2022 it has been ratified by 137 parties, which includes 136 UN member states and the European Union.

Concerns have been expressed that the added bureaucracy and legislation could be damaging to the monitoring and collection of biodiversity, to conservation, to the international response to infectious diseases, and to research.[1][2]

Aims and scope

The Nagoya Protocol applies to genetic resources that are covered by the CBD, and to the benefits arising from their utilization. The protocol also covers traditional knowledge associated with genetic resources that are covered by the CBD and the benefits arising from its utilization.

Its aim is the implementation of one of the three objectives of the CBD: the fair and equitable sharing of benefits arising out of the utilization of genetic resources, thereby contributing to the conservation and sustainable use of biodiversity.[3]

Adoption and ratification

The protocol was adopted on 29 October 2010 in Nagoya, Japan, at the tenth meeting of the Conference of the Parties, held from 18 to 29 October 2010[4] and entered into force on 12 October 2014.

As of April 2022 it has been ratified by 137 parties, which includes 136 UN member states and the European Union.[5]

Obligations

The Nagoya Protocol sets out obligations for its contracting parties to take measures in relation to access to genetic resources, benefit-sharing and compliance.

Access obligations

Domestic-level access measures aim to:

  • Create legal certainty, clarity, and transparency
  • Provide fair and non-arbitrary rules and procedures
  • Establish clear rules and procedures for prior informed consent and mutually agreed on terms
  • Provide for issuance of a permit or equivalent when access is granted
  • Create conditions to promote and encourage research contributing to biodiversity conservation and sustainable use
  • Pay due regard to cases of present or imminent emergencies that threaten human, animal, or plant health
  • Consider the importance of genetic resources for food and agriculture for food security

Benefit-sharing obligations

Domestic-level benefit-sharing measures aim to provide for the fair and equitable sharing of benefits arising from the utilization of genetic resources with the contracting party providing genetic resources. Utilization includes research and development on the genetic or biochemical composition of genetic resources, as well as subsequent applications and commercialization. Sharing is subject to mutually agreed terms. Benefits may be monetary or non-monetary such as royalties and the sharing of research results.

Compliance obligations

Specific obligations to support compliance with the domestic legislation or regulatory requirements of the contracting party providing genetic resources, and contractual obligations reflected in mutually agreed terms, are a significant innovation of the Nagoya Protocol.

Contracting parties are to:

  • Take measures providing that genetic resources utilized within their jurisdiction have been accessed in accordance with prior informed consent, and that mutually agreed terms have been established, as required by another contracting party
  • Cooperate in cases of an alleged violation of another contracting party's requirements
  • Encourage contractual provisions on dispute resolution in mutually agreed terms
  • Ensure an opportunity is available to seek recourse under their legal systems when disputes arise from mutually agreed terms (MAT)
  • Take measures regarding access to justice
  • Monitor the use of genetic resources after they leave a country by designating effective checkpoints at every stage of the value chain: research, development, innovation, pre-commercialization, or commercialization

Implementation

The Nagoya Protocol's success will require effective implementation at the domestic level. A range of tools and mechanisms provided by the Nagoya Protocol will assist contracting parties including:

  • Establishing national focal points (NFPs) and competent national authorities (CNAs) to serve as contact points for information, grant access, or cooperate on issues of compliance
  • An Access and Benefit-sharing Clearing-House to share information, such as domestic regulatory ABS requirements or information on NFPs and CNAs
  • Capacity-building to support key aspects of implementation.

Based on a country's self-assessment of national needs and priorities, capacity-building may help to:

  • Develop domestic ABS legislation to implement the Nagoya Protocol
  • Negotiate mutually-agreed terms
  • Develop in-country research capability and institutions
  • Raise awareness
  • Transfer technology
  • Target financial support for capacity-building and development initiatives through the GEF

Relationship to other international agreements

A growing number of Preferential Trade Agreements (PTAs) include provisions related to access to genetic resources or to the sharing of the benefits that arise out of their utilization. Indeed, some recent trade agreements, originating notably from Latin American countries, provide specific measures designed to facilitate the implementation of the ABS provisions contained in the Nagoya Protocol, including measures related to technical assistance, transparency and dispute settlement.[6]

Criticism

However, there are concerns that the added bureaucracy and legislation will, overall, be damaging to the monitoring and collection of biodiversity, to conservation, to the international response to infectious diseases, and to research.[7][2][8]

Many scientists have voiced concern over the protocol, fearing the increased red tape will hamper disease prevention and conservation efforts,[1] and that the threat of possible imprisonment of scientists will have a chilling effect on research.[7][8] Non-commercial biodiversity researchers and institutions such as natural history museums fear maintaining biological reference collections and exchanging material between institutions will become difficult.[2]

See also

References

  1. ^ a b Prathapan, K. Divakaran; Pethiyagoda, Rohan; Bawa, Kamaljit S.; Raven, Peter H.; Rajan, Priyadarsanan Dharma (2018). "When the cure kills—CBD limits biodiversity research". Science. 360 (6396): 1405–1406. Bibcode:2018Sci...360.1405P. doi:10.1126/science.aat9844. PMID 29954970. S2CID 206667464. Retrieved 28 November 2018.
  2. ^ a b c Watanabe, Myrna E. (June 2015). "The Nagoya Protocol on Access and Benefit Sharing—International treaty poses challenges for biological collections". BioScience. pp. 543–550. doi:10.1093/biosci/biv056.[dead link]
  3. ^ "Nagoya Protocol". 9 June 2015.
  4. ^ "Strategic Plan for Biodiversity 2011-2020, including Aichi Biodiversity Targets". Convention on Biological Diversity. 21 January 2020. Retrieved 17 September 2020.
  5. ^ "Parties to the Nagoya Protocol". Convention on Biological Diversity. 1 January 1970. Retrieved 2 June 2022.
  6. ^ Jean-Frédéric Morin and Mathilde Gauquelin, Trade Agreements as Vectors for the Nagoya Protocol's Implementation, CIGI papers, no 115, 2016, http://www.chaire-epi.ulaval.ca/sites/chaire-epi.ulaval.ca/files/publications/paper_no.115.pdf
  7. ^ a b Cressey, Daniel (2014). "Biopiracy ban stirs red-tape fears". Nature. 514 (7520): 14–15. Bibcode:2014Natur.514...14C. doi:10.1038/514014a. PMID 25279894. S2CID 4457904.
  8. ^ a b "A plea for open science on Zika". www.sciencemag.org. Retrieved 2 April 2016.

Further reading

Retrieved from "https://en.wikipedia.org/w/index.php?title=Nagoya_Protocol&oldid=1123901517"